{
    "title": "109_hr1396",
    "content": "The \"Counterfeit Drug Enforcement Act\" allows for recall authority regarding drugs under the Federal Food, Drug, and Cosmetic Act. The \"Counterfeit Drug Enforcement Act\" grants the Secretary the authority to issue an order to cease distribution of a drug if it poses a risk of serious health consequences or death. The order also requires notifying health professionals to stop administering or prescribing the drug. An informal hearing must be provided to the person subject to the order within 10 days. The Secretary has the authority to issue an order to cease distribution of a drug if it poses serious health risks. An informal hearing must be held within 10 days to discuss the actions required by the order. If inadequate grounds exist, the order will be vacated. If necessary, the order may be amended to include a drug recall with a specified timetable. The Secretary can issue an order to cease drug distribution if it poses health risks, with the option to amend the order to include a drug recall with a specified timetable and periodic progress reports. The amended order does not include recall of drugs from individuals but requires notice to individuals at risk. Health professionals may assist in notifying individuals at risk. SEC. 3. Sale or trade of prescription drugs knowingly caused to be adulterated or misbranded; knowing purchase or trade. Criminal penalties for knowingly causing drugs to be adulterated or misbranded include fines, imprisonment, or both. Manufacturers must notify the FDA about certain drugs. The FDA Amendment Act requires drug manufacturers to report any information suggesting a violation within 48 hours. Additionally, $60 million is authorized for FDA inspections and investigations related to drug violations from 2006 to 2010."
}